These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17210590)

  • 1. Epoetin trials: randomised controlled trials don't always mimic observational data.
    Roger SD; Levin A
    Nephrol Dial Transplant; 2007 Mar; 22(3):684-6. PubMed ID: 17210590
    [No Abstract]   [Full Text] [Related]  

  • 2. Anemia and response to epoetin alfa: the cause of anemia matters!
    Dharmarajan TS
    J Am Geriatr Soc; 2008 Aug; 56(8):1574-5. PubMed ID: 18808607
    [No Abstract]   [Full Text] [Related]  

  • 3. Anaemia of CKD--the CHOIR study revisited.
    Singh AK; Szczech L; Tang KL; Barnhart H; Sapp S; Wolfson M; Reddan D
    Nephrol Dial Transplant; 2007 Jul; 22(7):1806-10. PubMed ID: 17420166
    [No Abstract]   [Full Text] [Related]  

  • 4. Current and future challenges in anaemia management.
    Levin A; Locatelli F; Muirhead N; Ritz E
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi1-2. PubMed ID: 15958819
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to the publication: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer.
    Gascón P; Ludwig H
    Eur J Cancer; 2005 Dec; 41(18):2789-91. PubMed ID: 16253500
    [No Abstract]   [Full Text] [Related]  

  • 6. Relative mortality and epoetin alpha dose among hemodialysis patients.
    Coyne DW
    Am J Kidney Dis; 2008 May; 51(5):866-7; author reply 867. PubMed ID: 18436101
    [No Abstract]   [Full Text] [Related]  

  • 7. Relative mortality and epoetin alpha dose in hemodialysis patients.
    Cotter DJ; Thamer M; Zhang Y
    Am J Kidney Dis; 2008 May; 51(5):865; author reply 865-6. PubMed ID: 18436099
    [No Abstract]   [Full Text] [Related]  

  • 8. Epoetin bubble: a severe German case Honi soit qui mal y pense.
    Wizemann V
    Nephrol Dial Transplant; 2011 May; 26(5):1750-2; author reply 1752. PubMed ID: 21378149
    [No Abstract]   [Full Text] [Related]  

  • 9. Anemia: dialysis patients experiences.
    Schatell D; Witten B
    Nephrol News Issues; 2004 Nov; 18(12):49-54. PubMed ID: 15595502
    [No Abstract]   [Full Text] [Related]  

  • 10. A lesson from the EPO mess: stop the cost shifting.
    Amerling R
    Nephrol News Issues; 2007 Jul; 21(8):52, 54-5, 68. PubMed ID: 17688232
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epoetin alfa: future directions and future research.
    Ludwig H; Hudis CA; Goss G; Leyland-Jones B
    Oncologist; 2004; 9 Suppl 5():70-3. PubMed ID: 15591424
    [No Abstract]   [Full Text] [Related]  

  • 13. Has economics overshadowed our clinical approaches to EPO?
    Sullivan JD
    Nephrol News Issues; 2007 Jul; 21(8):56, 58-9, 68. PubMed ID: 17688233
    [No Abstract]   [Full Text] [Related]  

  • 14. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa.
    Agnihotri P; Telfer M; Butt Z; Jella A; Cella D; Kozma CM; Ahuja M; Riaz S; Akamah J
    J Am Geriatr Soc; 2007 Oct; 55(10):1557-65. PubMed ID: 17697104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety concerns about perisurgical epoetin treatment: should we add antiplatelet drugs to perisurgical epoetin alfa treatment?
    Basora M; Fita G; Matute P; Díaz-Ricart M
    J Cardiothorac Vasc Anesth; 2007 Aug; 21(4):623-4. PubMed ID: 17678803
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.
    Rossert J; Gassmann-Mayer C; Frei D; McClellan W
    Nephrol Dial Transplant; 2007 Mar; 22(3):794-800. PubMed ID: 17210593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TlpTLE: epotin and pure red-cell aplasia: what do we have?
    Massimo G; Daria M; Giorgina PB; Alberto J
    Med Sci Monit; 2003 Jul; 9(7):LE18. PubMed ID: 12956116
    [No Abstract]   [Full Text] [Related]  

  • 19. The normal hematocrit study--follow-up.
    Besarab A; Goodkin DA; Nissenson AR;
    N Engl J Med; 2008 Jan; 358(4):433-4. PubMed ID: 18216370
    [No Abstract]   [Full Text] [Related]  

  • 20. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
    Tonelli M; Owen WF; Jindal K; Winkelmayer WC; Manns B
    Kidney Int; 2004 Oct; 66(4):1712; author reply 1712-3. PubMed ID: 15458473
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.